Biotech / Medical
MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data
An SI Board Since September 2017
Posts SubjectMarks Bans Symbol
2 1 0 mdna
Emcee:  BioHero Type:  Moderated
Here is a very attractive and brutally undervalued canadian company called Medicenna (MDNA.TO) which is listed since March thats why its also undicovered . This Cancer Play has a Phase 2 trial in recurrent Glioblastoma ongoing a $650 Million Market , they expect to complete enrollment by year end and to report results in early Q1 2018 . If the results are positive then they can file for accelerated approval in 2H 2018 and this makes this company with a terrible low valuation of only C$ 36 Million a super attractive opportunity which has 10 bagger potential easily on positive phase 2 results in Q1 2018 and FDA approval .Please do your own DD and realize the mega potential .GL

Medicenna Therapeutics (MDNA.TO)

Market Cap C$36 Million
Cash : C$ 20 Million << enough untill Q1 2019
Price : $1.50

Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )

Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval

New Presentation

Fact Sheet

Insider Ownership :

Aries Biologics, Inc. 5 500 000
Rosemina Merchant 5 050 000
Fahar Merchant 5 050 000
Elizabeth Williams 5 300
Chandrakant J. Panchal, PhD 1 000
Trevor P. Wong-Chor 714

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.